News tagged with her2
Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Jan 16, 2012 |
5 / 5 (2) |
0
|
Researchers use light to measure cancer cells' response to treatment
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon ...
Dec 20, 2011 |
5 / 5 (1) |
0
New study shows biopsy of recurrent breast cancer can alter treatment
A second, larger clinical research study led by breast cancer specialists at Princess Margaret Hospital (PMH) has again proven that comparing a new biopsy of progressing or recurring cancer with that of the original cancer ...
Nov 28, 2011 |
5 / 5 (1) |
0
|
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such ...
Jul 05, 2011 |
not rated yet |
0
Breast cancer treatment shows benefit for women with small, localized disease
Memorial Sloan-Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2-positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin), ...
Jun 28, 2011 |
not rated yet |
0
Turning off cancer's growth signals
One hallmark of cancer cells is uncontrollable growth, provoked by inappropriate signals that instruct the cells to keep dividing. Researchers at MIT and Brigham and Women’s Hospital have now identified ...
Jun 13, 2011 |
4.2 / 5 (6) |
2
|
Scientists identify overactive genes in aggressive breast cancers
Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that ...
Jun 01, 2011 |
not rated yet |
0
|
Protein snapshots reveal clues to breast cancer outcomes
Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond ...
May 05, 2011 |
not rated yet |
0
Combination overcomes breast cancer resistance to herceptin
Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson ...
Mar 13, 2011 |
4 / 5 (2) |
0
|
Researchers discover signaling pathway crucial to acute lung injury
Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury (ALI). The data, obtained from cells, animals and ALI patients, suggest several potential ...
Jan 31, 2011 |
not rated yet |
0
Tracking therapeutic nanoparticles that target breast tumors
Researchers at Rice University, collaborating with investigators at the Baylor College of Medicine, have used two different types of imaging technologies to track the delivery of a therapeutic nanoparticle to breast tumors. ...
Nanotechnology / Bio & Medicine
Dec 17, 2010 |
5 / 5 (2) |
0
|
I-SPY 2 study speeds up treatment for breast cancer
A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O'Connor Thompson Breast Center at the University of Colorado Hospital.
Nov 19, 2010 |
5 / 5 (1) |
0
Fox Chase clinical trial tests first of its kind antibody
Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type ...
Jun 04, 2010 |
not rated yet |
0
Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.
May 06, 2010 |
not rated yet |
0
New way discovered to predict which breast cancer patients should be treated with anthracyclines
An international team of researchers has discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics.
Mar 25, 2010 |
not rated yet |
0
HER2/neu
HER2/neu (also known as ErbB-2) stands for "Human Epidermal growth factor Receptor 2" and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2/neu has also been designated as CD340 (cluster of differentiation 340) and p185. It is encoded by the ERBB2 gene.
For more information about HER2/neu, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
